International Real-World Analysis of Efficacy and Safety of Lorlatinib Through Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC

Lorlatinib exhibited meaningful activity in TKI-refractory ALK+ or ROS1+ patients with NSCLC enrolled in early or expanded access programs. READ ARTICLE

Journal of Thoracic Oncology DOI: 10.1016/j.jtho.2020.04.019

Authors: Viola W. Zhu, Yen-Ting Lin, Dong-Wan Kim, Herbert H. Loong, Misako Nagasaka, Hao To, Yvonne Li-En Ang, Chan-Young Ock, Nishan Tchekmedyian, Sai-Hong Ignatius Ou, Nicholas L. Syn, Thanyanan Reungwetwattana, Chia-Chi Lin, Ross A. Soo